GINKGO BIOWORKS HOLDINGS INC CLASS (DNA) competitors & alternatives
Health Care · NYSE
GINKGO BIOWORKS HOLDINGS INC CLASS (DNA)'s top competitors and alternatives — its most similar public companies — include TWIST BIOSCIENCE CORP (TWST), CODEXIS INC (CDXS), MARAVAI LIFESCIENCES HOLDINGS INC (MRVI), RECURSION PHARMACEUTICALS INC CLAS (RXRX), Bruker (BRKR), GENERATE BIOMEDICINES INC (GENB), Bio-Techne (TECH), ABSCI CORP (ABSI), TANGO THERAPEUTICS INC (TNGX), NURIX THERAPEUTICS INC (NRIX), Agilent Technologies (A) and OMNIAB INC (OABI). These are GINKGO BIOWORKS HOLDINGS INC CLASS's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top DNA competitors & alternatives
-
TWIST BIOSCIENCE CORPTWSTHealth Care
Twist Bioscience is a synthetic DNA synthesis platform company that enables the design and production of custom DNA molecules for drug development,…
$94.21 (as of 2026-07-22) · market cap $5.8B
-
CODEXIS INCCDXSHealth Care
Codexis leverages its proprietary directed evolution technology to engineer high-performance enzymes that optimize the manufacturing of small molecule and…
$2.06 (as of 2026-07-22) · market cap $200M
-
MARAVAI LIFESCIENCES HOLDINGS INCMRVIHealth Care
Maravai LifeSciences produces critical reagents and manufacturing services for mRNA vaccines and therapies, with CleanCap and TriLink products serving large…
$7.10 (as of 2026-07-22) · market cap $1.8B
-
RECURSION PHARMACEUTICALS INC CLASRXRXHealth Care
Recursion is a clinical-stage TechBio company using an AI-native operating system and massive biological datasets to industrialize and accelerate the drug…
$2.98 (as of 2026-07-22) · market cap $1.6B
-
BrukerBRKRHealth Care
Bruker is a global leader in high-performance analytical instrumentation and diagnostic solutions for life sciences and materials research, enabling structural…
$59.74 (as of 2026-07-22) · market cap $9.1B
-
GENERATE BIOMEDICINES INCGENBHealth Care
Generate Biomedicines is a clinical-stage biotechnology company leveraging generative artificial intelligence to design novel, programmable protein…
$13.90 (as of 2026-07-22) · market cap $1.8B
-
Bio-TechneTECHHealth Care
A leading life sciences company providing essential reagents, analytical tools, and bio-manufacturing solutions for research and clinical diagnostics.
$71.78 (as of 2026-07-22) · market cap $11.2B
-
ABSCI CORPABSIHealth Care
Absci is a clinical-stage drug developer leveraging a generative AI platform to rapidly design and validate novel, differentiated antibody therapeutics for…
$8.24 (as of 2026-07-22) · market cap $1.4B
-
TANGO THERAPEUTICS INCTNGXHealth Care
A precision oncology company utilizing a proprietary functional genomics platform to discover and develop targeted, synthetic-lethal cancer therapies.
$28.10 (as of 2026-07-22) · market cap $4.6B
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
Agilent TechnologiesAHealth Care
A diversified healthcare and life sciences company providing analytical instruments, software, and services for pharmaceutical, chemical, and clinical…
$133.46 (as of 2026-07-22) · market cap $37.6B
-
OMNIAB INCOABIHealth Care
OmniAb provides a proprietary, AI-enhanced transgenic animal platform that accelerates the discovery of human antibody therapeutics for global pharmaceutical…
$2.11 (as of 2026-07-22) · market cap $300M
Not quite? Describe exactly what you want →
Peers are GINKGO BIOWORKS HOLDINGS INC CLASS's closest public companies by shared sub-industry, sector and business themes. See the full profile: GINKGO BIOWORKS HOLDINGS INC CLASS (DNA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.